Immunomedics Inc. (IMMU) Stock Quote

Detailed Quote for Immunomedics Inc. (IMMU) 
$ 3.68   -0.02 (-0.54%) Volume: 268.53 k 4:00 PM EST Feb 10, 2012
Today 5d 1m 3m 1y more
Last Price
3.68
Change $
0.02
Change %
0.54%
Tick
N/A
Bid
N/A
Bid Size
0
Ask
N/A
Ask Size
0
Open
3.67
High
3.72
Low
3.61
Prev Close
3.70
Last Trade
4:00
Volume
268.53 k
52 Wk Hi
4.465
52 Wk Low
2.85
Market Cap
277.93 m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
75,525,231
EPS (TTM)
0.13
PE Ratio
28.50
Exchange
NSD
News and Media for Immunomedics Inc.  (IMMU) 
Sector News | Topic News
News for IMMU
Wed, Feb 08, 2012
8:30 AM Immunomedics Announces Second Quarter Fiscal 2012 Results and Clinical Program Developments - Globe Newswire
Tue, Jan 31, 2012
8:30 AM Immunomedics Awarded Broad Patent for Anti-CD20 and Anti-CD22 Combination Therapy - Globe Newswire
Fri, Jan 20, 2012
12:07 PM Immunomedics Reports Final Results From Phase Ib/II Study of Yttrium-90-Labeled Clivatuzumab Tetraxetan and Gemcitabine in Advanced Pancreatic Cancer - Globe Newswire
Wed, Jan 18, 2012
8:30 AM Immunomedics Reports Clivatuzumab-Based Blood Test Highly Sensitive and Specific for Early-Stage Pancreatic Cancer Detection - Globe Newswire
Thu, Jan 12, 2012
8:30 AM Immunomedics Announces Presentations at Gastrointestinal Cancers Symposium Showcasing Advances in Pancreatic Cancer Diagnosis and Therapy - Globe Newswire
Wed, Dec 28, 2011
1:00 AM Immunomedics and UCB Announce Restructuring of Epratuzumab License Agreement - Globe Newswire
Wed, Dec 14, 2011
8:30 AM Immunomedics Awarded New Patent for Improved Cell Lines for Protein Therapeutic Manufacturing - Globe Newswire
Tue, Dec 13, 2011
8:30 AM Immunomedics Announces Results From Two Clinical Trials at Hematology Conference - Globe Newswire
Mon, Dec 12, 2011
8:00 PM Immunomedics Develops Novel Antibody-Based Therapeutics for Mantle Cell and Other Lymphomas - Globe Newswire
3:18 PM Immunomedics Reports Subcutaneous Injections of Low-Dose Veltuzumab Produced High Rates of Response in Relapsed Immune Thrombocytopenia - Globe Newswire
Fri, Dec 09, 2011
8:30 AM Immunomedics Creates Targeted Therapeutics for Solid Cancers - Globe Newswire
Wed, Dec 07, 2011
12:30 PM Immunomedics Announces Outcome of 2011 Annual Meeting of Stockholders - Globe Newswire
Tue, Dec 06, 2011
8:37 AM Immunomedics to Present at Oppenheimer 22nd Annual Healthcare Conference - Globe Newswire
Wed, Nov 16, 2011
9:35 AM Immunomedics' Product Candidates to be Presented at the 2011 Annual Meeting of the American Society of Hematology - Globe Newswire
Tue, Nov 15, 2011
8:30 AM Immunomedics Awarded Additional U.S. Patent for Anti-CD20 Treatment of Autoimmune Diseases - Globe Newswire
Fri, Nov 11, 2011
8:15 AM Immunomedics Receives Thomas Alva Edison Patent Award From Research & Development Council of New Jersey - Globe Newswire
Tue, Nov 08, 2011
2:00 AM Epratuzumab Phase IIB Data Demonstrated Sensitivity of BICLA, a Novel BILAG-Based Composite Endpoint - Globe Newswire
Mon, Nov 07, 2011
8:30 AM Immunomedics to Participate in Upcoming Conferences - Globe Newswire
Fri, Nov 04, 2011
8:30 AM Immunomedics Announces First Quarter Fiscal 2012 Results and Clinical Program Developments - Globe Newswire
Wed, Nov 02, 2011
11:17 AM Immunomedics Announces FDA Allows Resumption of Clivatuzumab Tetraxetan Clinical Trial - Globe Newswire
More News for IMMU >>

Tags for Immunomedics Inc.

Research stocks or mutual funds related to Immunomedics Inc. by keywords or tags. Find companies that have a similar focus to IMMU. The keywords below have been associated to IMMU by either user submission or electronic means.

corporate governance quotient investor relations company corporate financial clinical development clinical cost corporate governance training Commercial Physical And Biological Research (8731) disney annual report biotech europe hong kong stock quote board of director clinical diagnostics financial information financial annual report europe pharmaceuticals annual report annual reports disney corporate governance financial report corporate governance issues clinical research medical device distributor business development europe investor relations data define corporate governance board of directors role good corporate governance nyse stock quote clinical trials industry online investor relations corporate governance disclosure board of directors governance board governance role of the board of directors Drugs annual report of company europe profile corporate annual report good governance pharma clinical trials antibody manufacturing 3m annual report financial stock report what is it governance corporate governance and compliance compliance duties of directors financial investor clinical trials europe pharmaceutical distributor

 

NYE - Equity | NYE - ETF | AMX - Equity | AMX - ETF | NSD - Equity | NSD - ETF
NMF - ETF | NMF - Money Market Fund | NMF - Mutual Fund | OTC - Equity | OTO - Equity | OTO - ETF | OTO - Mutual Fund
CNQ - Equity | CBO - Equity | BDM - Equity | TSX - Equity | TSX - ETF | TSX - Mutual Fund | TSV - Equity | TSV - Mutual Fund

Dow Jones Composite Index | Dow Jones Industrial Avg | Dow Jones Transportation Avg | Dow Jones Utiliy Index | NASDAQ 100
Russell 1000 | Russell 2000 | Russell 3000 | Russell Microcap | Russell Midcap | S&P 500 | S&P MidCap 400 | S&P/TSX 60 | S&P/TSX MidCap

Recently Added Symbols   Firms   Find Financial Advisors

Advisors by Name: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

RIAs by Name: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Tags: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Insiders: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

All information displayed and available herein is on an "as is", "as available" basis and neither InvestorPoint.com nor any of its underlying service providers, information providers, licensors, employees, distributors or agents make any representations as to the suitability of our service or the materials for any purpose. The information is not intended for trading purposes or advice. We specifically disclaim any representations or warranties, express or implied, including, without limitation, any representations or warranties of merchantability or fitness for a particular purpose. InvestorPoint.com is not an investment adviser. We do not: (a) give investment advice, (b) advocate the purchase or sale of any security or investment and (c) provide, endorse or review any information or data contained herein. We do not guarantee the accuracy of the information and data supplied by information providers. We are not liable or responsible for the quality, accuracy or reliability of this information. You should always seek the assistance of a professional for investment advice.

Copyright © 2010 InvestorPoint.com All rights reserved.